Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Novel Inhibitors of Interleukin-6 for Kaposi Sarcoma Therapy

Posted Oct 27 2009 5:00pm

Description of Invention:
The cancer therapy market is forecast to reach $40.9 billion by 2012. With immunosuppressant drugs set for phenomenal growth over the next six years, revenues could reach $26.2 billion by 2014. One market for which there is a significant need for new therapies is cancers induced by Kaposi Sarcoma-associated Herpesvirus (KSHV).

Researchers at the National Cancer Institute have identified novel nucleic acid sequences that act through a unique mechanism to inhibit the expression of interleukin-6 that occurs in cancerous cells transformed by KSHV infection and which promotes cancer cell proliferation. The researchers have also identified a key protein involved in the mechanism which could be inhibited using antibodies.

These inhibitors are likely to be accepted in the marketplace because their unique specificity in mechanism of action gives them a distinct advantage over the mechanisms of other existing therapies.

Applications:
  • Therapies for KSHV-induced cancers (Kaposi sarcoma (KS), primary effusion lymphoma (PEL) and multicentric Castleman disease (MCD)
  • Therapies for KSHV infection
  • Therapies for interleukin-6 associated inflammatory diseases
  • Immunosuppression of interleukin-6


Advantages:
  • Utilizes available small-molecule and antibody technologies
  • Targets a key pathway in interleukin-6 production
  • Specificity of mechanism of action may reduce/limit potential side-effects


Development Status:
Pre-clinical

Inventors:
Zhi-Ming Zheng (NCI)
Jeong-Gu Kang (NCI)


Patent Status:
HHS, Reference No. E-296-2009/0
US, Application No. 61/241,678 filed 11 Sep 2009


Relevant Publication:
  1. JG Kang et al. KSHV infection induces IL6 expression by interrupting microRNA-mediated translational repression. Submitted.


Licensing Status:
Available for licensing.

Collaborative Research Opportunity:
The NCI Center for Cancer Research, HIV and AIDS Malignancy Branch, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.


Portfolios:
Cancer
Cancer - Therapeutics
Gene Based Therapies
Gene Based Therapies - Therapeutics



For Additional Information Please Contact:
Patrick McCue Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: McCuepat@mail.nih.gov
Phone: 301-496-7057
Fax: 301-402-0220


Ref No: 2026

Updated: 10/2009

Post a comment
Write a comment:

Related Searches